HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Peroni, D.G. Articles by Boner, A.L. Search for Related Content PubMed PubMed Citation Articles by Peroni, D.G. Articles by Boner, A.L.

The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children

¹ Clinica Pediatrica, University of Verona, Verona, ² Istituto Pio XII, Misurina and ³ Dept of Statistics, University of Trento, Trento, Italy

CORRESPONDENCE: P. Diego, Clinica Pediatrica Universita' di Verona, Policlinico GB Rossi, Via Menegone, 37134, Verona, Italy. Fax: 39 0458200993. E-mail: peroni.diego@tiscalinet.it

Keywords: asthma, childhood, exercise-induced bronchoconstriction, loratadine, montelukast

Received: April 17, 2001
Accepted March 1, 2002

The aim of the study was to evaluate the protective effect of single-dose, combination treatment comprising montelukast (5 mg) and loratadine (10 mg), on exercise-induced bronchoconstriction in asthmatic children. The combination was compared to placebo, loratadine and montelukast alone.

Nineteen children were enrolled in a double-blind randomised, single-dose, crossover study. For each treatment patients undertook two treadmill exercise tests, 2 and 12 h respectively after single-dose administration.

No significant differences were seen in the maximum fall in forced expiratory volume in one second (FEV₁) 2 h after treatment and placebo. Whereas significant differences in maximum fall in FEV₁ were observed between treatment groups 12 h after administration. Loratadine alone did not show any significant protection or any additional effect in comparison with montelukast alone. Single doses of montelukast and montelukast plus loratadine were significantly more effective than loratadine at 12 h.

The present study, performed using single-dose treatments, demonstrated that maximal protective effect by montelukast was obtained 12 h after dosing and that montelukast plus loratadine did not result in significant additive bronchoprotective effects on exercise-induced bronchoconstriction.

This article has been cited by other articles:

				T. S. Hallstrand, M. W. Moody, M. M. Wurfel, L. B. Schwartz, W. R. Henderson Jr., and M. L. Aitken Inflammatory Basis of Exercise-induced Bronchoconstriction Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 679 - 686. [Abstract] [Full Text] [PDF]

				W. Busse and M. Kraft Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy Chest, April 1, 2005; 127(4): 1312 - 1326. [Abstract] [Full Text] [PDF]